Table 1.
Patients’ characteristics.
| Characteristics | Remdesivir Cohort (n = 243) |
Nirmatrelvir/Ritonavir Cohort (n = 223) |
p Value |
|---|---|---|---|
| Age (years), median (range) | 64 (19–92) | 65 (19–90) | 0.4 |
| • 0–40 years, n (%) | 18 (8) | 19 (9) | 0.28 |
| • 41–60 years, n (%) | 86 (35) | 66 (30) | |
| • 61–70 years, n (%) | 49 (20) | 60 (27) | |
| • >71 years, n (%) | 90 (37) | 78 (35) | |
| Male, n (%) | 150 (62) | 131 (59) | 0.63 |
| Baseline disease, n (%) | 0.34 | ||
| • AML | 41 (17) | 26 (12) | |
| • ALL | 9 (4) | 6 (3) | |
| • MDS | 21 (9) | 13 (6) | |
| • CMPD | 8 (3) | 7 (3) | |
| • B-cell NHL | 78 (32) | 88 (40) | |
| • T-cell NHL | 7 (3) | 2 (1) | |
| • CLL | 20 (8) | 12 (5) | |
| • Plasmatic cell disorder | 38 (16) | 57 (25.5) | |
| • HD | 12 (5) | 11 (5) | |
| • AA or others | 6 (2) | 1 (0.5) | |
| Time from last therapy to COVID-19 | 0.61 | ||
| • <6 months | 182 (75) | 158 (71) | |
| • 6–12 months | 19 (8) | 20 (9) | |
| • >12 months or not treated | 42 (17) | 45 (20) | |
| Anti-CD 20 and time from to COVID-19, n (%) | 74 (31) | 88 (40) | 0.13 |
| • <6 months | 56 (24) | 68 (31) | |
| • 6–12 months | 6 (3) | 3 (1.5) | |
| • >12 months or not treated | 12 (5) | 17 (8) | |
| Cell therapy, n (%) | 94 (39) | 81 (36) | 0.63 |
| - ASCT, n (%) | 36 (15) | 41 (18) | |
| - Allo-SCT donor, n (%) | 46 (19) | 25 (11) | |
| • HLA identical sibling | 21 (9) | 8 (3.6) | |
| • Unrelated Donor | 12 (5) | 9 (4) | |
| • Haplo-identical family donor | 12 (5) | 8 (3.6) | |
| • UCBT | 1 (0.5) | 0 | |
| - CAR-T type, n (%) | 12 (5) | 15 (7) | |
| • Axi-cell | 6 | 6 | |
| • Tisa-cell | 1 | 2 | |
| • Anti-BCMA | 1 | 1 | |
| • ARI-001 (anti-CD19) | 4 | 5 | |
| Corticosteroids at the time of COVID-19, n (%) | 68 (28) | 48 (22) | 0.1 |
| Number of vaccine doses, n (%) | 0.017 | ||
| • 0, n (%) | 22 (9) | 14 (6) | |
| • 1, n (%) | 8 (3) | 8 (4) | |
| • 2, n (%) | 56 (23) | 29 (13) | |
| • 3, n (%) | 87 (36) | 92 (41) | |
| • >3, n (%) | 70 (29) | 80 (36) | |
| Vaccination status ©, n (%) | 0.003 | ||
| • Incomplete | 86 (36) | 51 (23) | |
| • Complete | 157 (64) | 172 (77) | |
| Tixagevimab/cilgavimab pre-exposure prophylaxis n (%) | 4 (1.6) | 8 (3.6) | 0.25 |
| Pulmonary/cardiovascular RF, n (%) | |||
| • Active smoking | 21 (9) | 21 (9) | 0.87 |
| • Arterial hypertension | 105 (43) | 79 (35) | 0.2 |
| • Cardiomyopathy | 49 (20) | 30 (14) | 0.14 |
| • Pulmonary disease | 33 (14) | 15 (7) | 0.05 |
| Overall mortality, n (%) | 50 (21) | 20 (9) | <0.001 |
| Median F/U after COVID-19, days (range) | 119 (3–549) | 136 (5–539) | 0.4 |
Abbreviations: AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; cMPD, chronic myeloproliferative disease; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; HD, Hodgkin lymphoma; AA, aplastic anemia; ASCT, autologous hematopoietic stem cell transplantation; allo-SCT, allogeneic hematopoietic stem cell transplantation; UCBT, umbilical cord blood transplantation; CAR-T, chimeric antigen receptor T-cell therapy; BCMA, B-cell maturation antigen; ARI-001, academic CART-T; F/U, follow-up. © Complete vaccination was defined as at least 3 vaccine doses, whereas incomplete include 2 or less.